Pfizer’s PARP inhibitor combo treatment passes primary endpoint — but details are slim

Pfizer acquired both Xtandi and Talzenna, a PARP inhibitor, in its $14 billion buyout of Medivation in 2016.

And in its Phase III TALAPRO-2 study, it combined the two drugs to treat patients with metastatic castration-resistant prostate cancer, or mCRPC for short, comparing them to Xtandi alone. Tuesday morning, Pfizer said that study met its primary endpoint of progression free survival — with a hazard ratio 0f 0.696. But it didn’t give many more details.